Thank you very much, Mr. Chair.
I want to thank all our witnesses for assisting us in our study of this bill.
Like Mr. Garneau, I am somewhat disappointed that the Apotex representatives are not here. We are very concerned about how long it took to deliver the medicines. We were told that it took far too long, but Mr. Dearden was not of the same opinion. Public officials who appeared before the committee at the beginning of the study agreed with him. Mr. Perry told us that his company handled everything promptly. We're really wondering what all that time was wasted on. That's why it would have been interesting to hear what Apotex representatives have to say about this.
Ms. MacLean, I'd like you to clarify some of your comments. You said that first-line generic medicines could be supplied at low cost because companies were competitive. So, first-line medicines are available at a lower cost. We need the same level of competition for second- and third-line medicines.
I'm just wondering how amendments to the current regime will help create more competition if Canada is the only country making such changes.